Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) tinted gains of +0.37% (+0.01 points) to US$2.71. The volume of 0.69 Million shares climbed down over an trading activity of 642.95 Million shares. EPS ratio determined by looking at last 12 month figures is -2.51. Over the same time span, the stock marked US$16.9 as its best level and the lowest price reached was US$1.96. The corporation has a market cap of US$63.63 Million.
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)’s earnings per share has been growing at a -12 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -53.4 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 91.2 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 4 think it is Hold. Recently, analysts have updated the overall rating to 3. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Insulet Corporation (NASDAQ:PODD) is worth US$5.14 Billion and has recently risen 0.37% to US$87.89. The latest exchange of 0.72 Million shares is below its average trading activity of 570.25 Million shares. The day began at US$88.53 but the price moved to US$86.28 at one point during the trading and finally capitulating to a session high of US$90. The stock tapped a 52-week high of US$102.89 while the mean 12-month price target for the shares is US$99.53.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 30.1, and a price to sales ratio of 10.58. For the past 5 years, the company’s revenue has grown 17%, while the company’s earnings per share has grown 15.8%. With an institutional ownership near 98.5%, it carries an earnings per share ratio of -0.4.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 8 brokerage firms polled by Factset Research. At present, 6 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.89.